Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INM 
InMed Pharmaceuticals Inc (INM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: INM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.77% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.08M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) - | Beta 0.28 | 52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 |
52 Weeks Range 1.72 - 9.38 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.65 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -168.9% | Operating Margin (TTM) -167.67% |
Management Effectiveness
Return on Assets (TTM) -44.64% | Return on Equity (TTM) -91.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 297344 | Price to Sales(TTM) 0.83 |
Enterprise Value 297344 | Price to Sales(TTM) 0.83 | ||
Enterprise Value to Revenue 0.06 | Enterprise Value to EBITDA 1 | Shares Outstanding 1207190 | Shares Floating 1205387 |
Shares Outstanding 1207190 | Shares Floating 1205387 | ||
Percent Insiders 1.45 | Percent Institutions 10.18 |
Upturn AI SWOT
InMed Pharmaceuticals Inc
Company Overview
History and Background
InMed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of novel cannabinoid-based therapies. Founded in 2014, InMed has focused on rare diseases with unmet medical needs. A key milestone was advancing their lead candidate, INM-755, into clinical trials for epidermolysis bullosa (EB).
Core Business Areas
- Drug Development: Focuses on developing cannabinoid-based therapies for diseases with high unmet medical needs. This involves preclinical research, clinical trials, and regulatory approvals.
- Intellectual Property: Building and maintaining a strong intellectual property portfolio around their cannabinoid-based drug candidates and manufacturing processes.
Leadership and Structure
The leadership team consists of seasoned executives with experience in drug development, regulatory affairs, and commercialization. The organizational structure includes research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- INM-755: A cannabinol (CBN) cream being developed for the treatment of epidermolysis bullosa (EB). It is currently in Phase 2 clinical trials. Market share data is not yet available as the product is not yet commercially available. Competitors include companies developing gene therapies and other topical treatments for EB, such as Abeona Therapeutics (ABEO) and Castle Creek Biosciences.
- INM-901: A biosynthetic cannabidivarin (CBDV) oral formulation being developed for neurological disorders. Preclinical development stage. Market share data is not yet available. Competitors are other cannabinoid based therapeutics.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. The cannabinoid-based drug development market is growing rapidly, driven by increasing acceptance of cannabis for medical use and advancements in cannabinoid research.
Positioning
InMed is positioned as a specialized biopharmaceutical company focused on developing cannabinoid-based therapies for rare diseases. Its competitive advantage lies in its proprietary drug delivery systems and its focus on underserved medical needs.
Total Addressable Market (TAM)
The global epidermolysis bullosa (EB) market is estimated to reach several billion dollars, and growing. InMed is positioned to capture a share of this TAM with INM-755, if approved. The TAM for neurological disorders treatable by INM-901 is also significant.
Upturn SWOT Analysis
Strengths
- Novel cannabinoid-based drug candidates
- Focus on rare diseases with high unmet medical needs
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on clinical trial success
- Limited product portfolio
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing acceptance of cannabinoid-based therapies
- Positive clinical trial results
Threats
- Regulatory hurdles
- Competition from other biopharmaceutical companies
- Clinical trial failures
- Funding challenges
Competitors and Market Share
Key Competitors
- ABEO
- CRBU
- VYNE
- GWPH
Competitive Landscape
InMed faces competition from larger, more established pharmaceutical companies with greater resources. However, InMed's focus on cannabinoid-based therapies and rare diseases provides a degree of differentiation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by advancing drug candidates through the clinical trial pipeline and securing funding. Early stage growth
Future Projections: Future growth depends on the success of clinical trials and regulatory approvals for INM-755 and INM-901. Analyst estimates vary widely due to the inherent risks of drug development.
Recent Initiatives: Recent initiatives include advancing INM-755 into Phase 2 clinical trials and continuing preclinical development of INM-901.
Summary
InMed Pharmaceuticals Inc. is a high-risk, high-reward investment. Their clinical program needs to prove itself. Success in clinical trials could result in rapid growth, while setbacks could significantly impact the company's valuation. Management of cash and resources is key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About InMed Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Vancouver, BC, Canada | ||
IPO Launch date 2020-11-12 | President, CEO & Director Mr. Eric A. Adams B.S. Chem., M.I.B. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13 | Website https://www.inmedpharma.com |
Full time employees 13 | Website https://www.inmedpharma.com | ||
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, which is a small molecule compound acting as a selective dual CB1 /CB2 agonist; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.